Template:Endocarditis Empiric Antibiotics - Revision history

Danbot: Add pediatric empiric dosing section

2026-03-20T13:03:26Z

Add pediatric empiric dosing section

← Older revision		Revision as of 13:03, 20 March 2026
Line 14:		Line 14:
	===[[Dental Procedure Prophylaxis]]===		===[[Dental Procedure Prophylaxis]]===
	{{Dental Procedure Endocarditis Prophylaxis Antibiotics}}		{{Dental Procedure Endocarditis Prophylaxis Antibiotics}}

			===Pediatric Empiric===
			*{{AntibioticDose\|disease=Endocarditis\|drug=Vancomycin\|dose=15mg/kg IV q6hrs (max 2g/dose)\|context=Pediatric Empiric\|population=Pediatric}} + {{AntibioticDose\|disease=Endocarditis\|drug=Gentamicin\|dose=1mg/kg IV q8hrs\|context=Pediatric Empiric\|population=Pediatric}}
			*{{AntibioticDose\|disease=Endocarditis\|drug=Nafcillin\|dose=50mg/kg IV q6hrs (max 2g/dose)\|context=Pediatric MSSA\|population=Pediatric}} if MSSA confirmed
			*{{AntibioticDose\|disease=Endocarditis\|drug=Ceftriaxone\|dose=100mg/kg/day IV divided q12h (max 4g/day)\|context=Pediatric Empiric\|population=Pediatric}} as alternative

Kxl328 at 14:50, 9 July 2020

2020-07-09T14:50:55Z

← Older revision		Revision as of 14:50, 9 July 2020
Line 14:		Line 14:
	===[[Dental Procedure Prophylaxis]]===		===[[Dental Procedure Prophylaxis]]===
	{{Dental Procedure Endocarditis Prophylaxis Antibiotics}}		{{Dental Procedure Endocarditis Prophylaxis Antibiotics}}

	~~===Miscellaneous===~~
	*No therapeutic anticoagulation necessary
	**Anticoagulation carries higher risk of bleeding without reducing embolic complication or mortality benefit<ref>Elkaryoni A et al. ANTICOAGULATION IN INFECTIVE ENDOCARDITIS: INSIGHTS FROM NATIONWIDE INPATIENT SAMPLE. Journal of the American College of Cardiology. Volume 73, Issue 9 Supplement 1, March 2019.</ref>
	*[[Septic pulmonary embolism]]
	**Most common culture growths were MSSA, MRSA, and candida
	**Furthermore, therapeutic anticoagulation not indicated for [[septic pulmonary embolism]]<ref>Li Zhao RY et al. Clinical characteristics of septic pulmonary embolism in adults: A systematic review. Respiratory Medicine. Volume 108, Issue 1, January 2014, Pages 1-8.</ref>

Kxl328 at 14:49, 9 July 2020

2020-07-09T14:49:36Z

← Older revision		Revision as of 14:49, 9 July 2020
Line 20:		Line 20:
	*[[Septic pulmonary embolism]]		*[[Septic pulmonary embolism]]
	**Most common culture growths were MSSA, MRSA, and candida		**Most common culture growths were MSSA, MRSA, and candida
	**Furthermore, therapeutic anticoagulation not indicated for [septic pulmonary embolism]<ref>Li Zhao RY et al. Clinical characteristics of septic pulmonary embolism in adults: A systematic review. Respiratory Medicine. Volume 108, Issue 1, January 2014, Pages 1-8.</ref>		**Furthermore, therapeutic anticoagulation not indicated for [[septic pulmonary embolism]]<ref>Li Zhao RY et al. Clinical characteristics of septic pulmonary embolism in adults: A systematic review. Respiratory Medicine. Volume 108, Issue 1, January 2014, Pages 1-8.</ref>

Kxl328 at 14:48, 9 July 2020

2020-07-09T14:48:41Z

← Older revision		Revision as of 14:48, 9 July 2020
Line 19:		Line 19:
	**Anticoagulation carries higher risk of bleeding without reducing embolic complication or mortality benefit<ref>Elkaryoni A et al. ANTICOAGULATION IN INFECTIVE ENDOCARDITIS: INSIGHTS FROM NATIONWIDE INPATIENT SAMPLE. Journal of the American College of Cardiology. Volume 73, Issue 9 Supplement 1, March 2019.</ref>		**Anticoagulation carries higher risk of bleeding without reducing embolic complication or mortality benefit<ref>Elkaryoni A et al. ANTICOAGULATION IN INFECTIVE ENDOCARDITIS: INSIGHTS FROM NATIONWIDE INPATIENT SAMPLE. Journal of the American College of Cardiology. Volume 73, Issue 9 Supplement 1, March 2019.</ref>
	*[[Septic pulmonary embolism]]		*[[Septic pulmonary embolism]]
	**Most common culture growths were MSSA, MRSA, and candida
	**Furthermore, therapeutic anticoagulation not indicated for [septic pulmonary embolism]<ref>Li Zhao RY et al. Clinical characteristics of septic pulmonary embolism in adults: A systematic review. Respiratory Medicine. Volume 108, Issue 1, January 2014, Pages 1-8.</ref>

	~~===Miscellaneous===~~
	*No therapeutic anticoagulation necessary
	**Anticoagulation carries higher risk of bleeding without reducing embolic complication or mortality benefit<ref>Elkaryoni A et al. ANTICOAGULATION IN INFECTIVE ENDOCARDITIS: INSIGHTS FROM NATIONWIDE INPATIENT SAMPLE. Journal of the American College of Cardiology. Volume 73, Issue 9 Supplement 1, March 2019.</ref>
	*[Septic pulmonary embolism]
	**Most common culture growths were MSSA, MRSA, and candida		**Most common culture growths were MSSA, MRSA, and candida
	**Furthermore, therapeutic anticoagulation not indicated for [septic pulmonary embolism]<ref>Li Zhao RY et al. Clinical characteristics of septic pulmonary embolism in adults: A systematic review. Respiratory Medicine. Volume 108, Issue 1, January 2014, Pages 1-8.</ref>		**Furthermore, therapeutic anticoagulation not indicated for [septic pulmonary embolism]<ref>Li Zhao RY et al. Clinical characteristics of septic pulmonary embolism in adults: A systematic review. Respiratory Medicine. Volume 108, Issue 1, January 2014, Pages 1-8.</ref>

Kxl328: /* Dental Procedure Prophylaxis */

2020-07-09T14:48:11Z

Dental Procedure Prophylaxis

← Older revision		Revision as of 14:48, 9 July 2020
Line 14:		Line 14:
	===[[Dental Procedure Prophylaxis]]===		===[[Dental Procedure Prophylaxis]]===
	{{Dental Procedure Endocarditis Prophylaxis Antibiotics}}		{{Dental Procedure Endocarditis Prophylaxis Antibiotics}}

			===Miscellaneous===
			*No therapeutic anticoagulation necessary
			**Anticoagulation carries higher risk of bleeding without reducing embolic complication or mortality benefit<ref>Elkaryoni A et al. ANTICOAGULATION IN INFECTIVE ENDOCARDITIS: INSIGHTS FROM NATIONWIDE INPATIENT SAMPLE. Journal of the American College of Cardiology. Volume 73, Issue 9 Supplement 1, March 2019.</ref>
			*[[Septic pulmonary embolism]]
			**Most common culture growths were MSSA, MRSA, and candida
			**Furthermore, therapeutic anticoagulation not indicated for [septic pulmonary embolism]<ref>Li Zhao RY et al. Clinical characteristics of septic pulmonary embolism in adults: A systematic review. Respiratory Medicine. Volume 108, Issue 1, January 2014, Pages 1-8.</ref>

	===Miscellaneous===		===Miscellaneous===

Kxl328: /* Dental Procedure Prophylaxis */

2020-07-09T14:47:40Z

Dental Procedure Prophylaxis

← Older revision		Revision as of 14:47, 9 July 2020
Line 14:		Line 14:
	===[[Dental Procedure Prophylaxis]]===		===[[Dental Procedure Prophylaxis]]===
	{{Dental Procedure Endocarditis Prophylaxis Antibiotics}}		{{Dental Procedure Endocarditis Prophylaxis Antibiotics}}

			===Miscellaneous===
			*No therapeutic anticoagulation necessary
			**Anticoagulation carries higher risk of bleeding without reducing embolic complication or mortality benefit<ref>Elkaryoni A et al. ANTICOAGULATION IN INFECTIVE ENDOCARDITIS: INSIGHTS FROM NATIONWIDE INPATIENT SAMPLE. Journal of the American College of Cardiology. Volume 73, Issue 9 Supplement 1, March 2019.</ref>
			*[Septic pulmonary embolism]
			**Most common culture growths were MSSA, MRSA, and candida
			**Furthermore, therapeutic anticoagulation not indicated for [septic pulmonary embolism]<ref>Li Zhao RY et al. Clinical characteristics of septic pulmonary embolism in adults: A systematic review. Respiratory Medicine. Volume 108, Issue 1, January 2014, Pages 1-8.</ref>

GregArmani: /* Dental Procedure Prophylaxis */

2015-08-07T03:10:08Z

Dental Procedure Prophylaxis

← Older revision		Revision as of 03:10, 7 August 2015
Line 12:		Line 12:
	;Late prosthetic valve endocarditis defined as ≥ 12 months post surgery<ref name="ESC Task Force"></ref>		;Late prosthetic valve endocarditis defined as ≥ 12 months post surgery<ref name="ESC Task Force"></ref>
	{{Prosthetic Valve Endocarditis Antibiotics Late}}		{{Prosthetic Valve Endocarditis Antibiotics Late}}
	===Dental Procedure Prophylaxis===		===[[Dental Procedure Prophylaxis]]===
	{{Dental Procedure Endocarditis Prophylaxis Antibiotics}}		{{Dental Procedure Endocarditis Prophylaxis Antibiotics}}

Yoshmd at 19:58, 6 April 2015

2015-04-06T19:58:22Z

← Older revision		Revision as of 19:58, 6 April 2015
Line 7:		Line 7:
	;Early prosthetic valve endocarditis defined as < 12 months post surgery<ref name="ESC Task Force"></ref>		;Early prosthetic valve endocarditis defined as < 12 months post surgery<ref name="ESC Task Force"></ref>
	{{Prosthetic Valve Endocarditis Antibiotics Early}}		{{Prosthetic Valve Endocarditis Antibiotics Early}}
			===IV Drug User without Prosthetic Valve===
			{{IVDA Endocarditis Antibiotics}}
	===Prosthetic Valve (Late)===		===Prosthetic Valve (Late)===
	;Late prosthetic valve endocarditis defined as ≥ 12 months post surgery<ref name="ESC Task Force"></ref>		;Late prosthetic valve endocarditis defined as ≥ 12 months post surgery<ref name="ESC Task Force"></ref>

Ostermayer at 14:59, 7 July 2014

2014-07-07T14:59:09Z

Ostermayer at 14:52, 7 July 2014

2014-07-07T14:52:13Z

← Older revision		Revision as of 14:52, 7 July 2014
Line 1:		Line 1:
	===Native Valves===		===Native Valves===
	'''Options:'''		'''Options:'''<ref>ESC Task Force Guidelines on the prevention, diagnosis, and treatment of infective endocarditis. European Heart Journal (2009) 30, 2369–2413 doi:10.1093/eurheartj/ehp285 [http://www.escardio.org/guidelines-surveys/esc-guidelines/guidelinesdocuments/guidelines-ie-ft.pdf PDF]</ref>
	{{Native Valve Endocarditis Antibiotics}}		{{Native Valve Endocarditis Antibiotics}}
	'''Suspected MRSA:'''		'''Suspected MRSA:'''
Line 10:		Line 10:
	;Late prosthetic valve endocarditis defined as ≥ 12 months post surgery		;Late prosthetic valve endocarditis defined as ≥ 12 months post surgery
	{{Prosthetic Valve Endocarditis Antibiotics Late}}		{{Prosthetic Valve Endocarditis Antibiotics Late}}
			===Dental Procedure Prophylaxis===
			{{Dental Procedure Endocarditis Prophylaxis Antibiotics}}

← Older revision		Revision as of 14:59, 7 July 2014
Line 1:		Line 1:
	===Native Valves===		===Native Valves===
	'''Options:'''<ref>ESC Task Force Guidelines on the prevention, diagnosis, and treatment of infective endocarditis. European Heart Journal (2009) 30, 2369–2413 doi:10.1093/eurheartj/ehp285 [http://www.escardio.org/guidelines-surveys/esc-guidelines/guidelinesdocuments/guidelines-ie-ft.pdf PDF]</ref>		'''Options:'''<ref name="ESC Task Force">ESC Task Force Guidelines on the prevention, diagnosis, and treatment of infective endocarditis. European Heart Journal (2009) 30, 2369–2413 doi:10.1093/eurheartj/ehp285 [http://www.escardio.org/guidelines-surveys/esc-guidelines/guidelinesdocuments/guidelines-ie-ft.pdf PDF]</ref>
	{{Native Valve Endocarditis Antibiotics}}		{{Native Valve Endocarditis Antibiotics}}
	'''Suspected MRSA:'''		'''Suspected MRSA:'''<ref name="ESC Task Force"></ref>
	{{MRSA Native Valve Endocarditis Antibiotics}}		{{MRSA Native Valve Endocarditis Antibiotics}}
	===Prosthetic Valves (Early)===		===Prosthetic Valves (Early)===
	;Early prosthetic valve endocarditis defined as < 12 months post surgery		;Early prosthetic valve endocarditis defined as < 12 months post surgery<ref name="ESC Task Force"></ref>
	{{Prosthetic Valve Endocarditis Antibiotics Early}}		{{Prosthetic Valve Endocarditis Antibiotics Early}}
	===Prosthetic Valve (Late)===		===Prosthetic Valve (Late)===
	;Late prosthetic valve endocarditis defined as ≥ 12 months post surgery		;Late prosthetic valve endocarditis defined as ≥ 12 months post surgery<ref name="ESC Task Force"></ref>
	{{Prosthetic Valve Endocarditis Antibiotics Late}}		{{Prosthetic Valve Endocarditis Antibiotics Late}}
	===Dental Procedure Prophylaxis===		===Dental Procedure Prophylaxis===
	{{Dental Procedure Endocarditis Prophylaxis Antibiotics}}		{{Dental Procedure Endocarditis Prophylaxis Antibiotics}}